AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02288052 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Writing program
Description: 6 weeks of at-home training (5days/week, 30minutes/day) using both pen-and-paper exercises and exercises on a writing tablet.
Study NCT02288052 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretch & Relaxation program
Description: 6 weeks of at-home training (5days/week, 30minutes/day) using a DVD with exercises.
Study NCT02959307 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Light Therapy
Description: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
Study NCT02959307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Light Therapy
Description: Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
Study NCT02959307 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Light Therapy
Description: The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
Study NCT04674410 — intervention group
Intervention type: DRUG
Intervention: Antibiotic
Description: Empiric antibiotic therapy, subdivided according to Community Acquired Pneumonia coverage vs Hospital Acquired Pneumonia coverage
Study NCT00330746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/m2 first dose then weekly at 250 mg/m2 until disease progression
Study NCT00330746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1200 mg/m2 days 1 and 8 every 3 weeks for a maximum of 6 cycles
Study NCT00330746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1200 mg/m2 IV days 1 and 8 every 3 weeks for a maximum of 6 cycles
Study NCT00330746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/m2 first dose followed by 250 mg/m2 weekly
Study NCT01755936 — intervention group
Intervention type: OTHER
Intervention: 72 hour Holter Monitor
Description: This will enable us to detect abnormal heart rhythms which may be associated with myocardial fibrosis
Study NCT03825172 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Caudal Epidural Ultrasonography
Description: Ultrasonographic Measurement
Study NCT02025257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
Study NCT01323166 — intervention group
Intervention type: PROCEDURE
Intervention: Excision of the levator muscle
Description: Cylindrical perineal excision including the levator muscle
Study NCT00786734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: 4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI
Study NCT00786734 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pitavastatin
Description: 4mg daily for 28 days after PCI
Study NCT03033004 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Cryolipolysis
Description: Treatment will be a cold exposure of the subcutaneous fat for 60 minutes using the Polarys device. Polarys is a commercially available cryolipolitic device.
Study NCT03033004 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contrast Cryolipolysis
Description: Treatment will consist of a heat exposure of the subcutaneous fat for 10 minutes followed by 60 minutes of cold exposure and 10 minutes of heat exposure again. Cold and heat will be provided by the Polarys device. Polarys is a commercially available cryolipolitic device.
Study NCT03033004 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reperfusion Cryolipolysis
Description: Treatment will be a cold exposure of the subcutaneous fat for 60 minutes followed by 10 minutes of heat exposure using the Polarys device. Polarys is a commercially available cryolipolitic device.
Study NCT04532944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: imaging of energy dysfunction
Description: 7T sodium imaging, phosphorus spectroscopy and 3T diffusion-weighted spectroscopy
Study NCT02671227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal bupivacaine 15 mg.
Description: intrathecal bupivacaine 15 mg.
Study NCT02805101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: Biodentine is going to be used as the sealing agent for the perforation.
Study NCT04029441 — intervention group
Intervention type: OTHER
Intervention: the eradication Hp
Description: the eradication of Hp based on antimicrobial susceptibility test
Study NCT01414595 — intervention group
Intervention type: GENETIC
Intervention: DNA analysis
Study NCT02805101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: MTA is going to be used as the sealing agent for the perforation.
Study NCT00556803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: radiofrequency ablation
Study NCT00556803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE after RFA
Description: TACE after RFA within one month
Study NCT01509846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose
Description: Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^8 vp/mL administered on Day 0
Study NCT00939510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: All patients will receive GM-CSF at a dose of 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week. No dose escalation or de-escalations will be made to GM-CSF.
Study NCT00939510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Lenalidomide will be administered at 25 mg/day orally on days 1-21 of a 28-day cycle. Initially 6 patients will be entered at the 25 mg/day level. If 0 or 1 patients have a dose limiting toxicity, then the 25 mg lenalidomide + GM-CSF 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week will be accepted as the phase II dose.
Study NCT00939510 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Prior to the initiation of each cycle of therapy for the first 3 cycles, and at discontinuation from study blood will be collected for assessments of a prostate cancer specific immune response.
Study NCT04133337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib Mesylate Tablets
Study NCT04133337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: Camrelizumab for Injection
Study NCT01509846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses
Description: Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^9 vp/mL administered on Days 0, 28, and 56
Study NCT01414595 — intervention group
Intervention type: GENETIC
Intervention: DNA methylation analysis
Study NCT01414595 — intervention group
Intervention type: GENETIC
Intervention: RNA analysis
Study NCT01414595 — intervention group
Intervention type: GENETIC
Intervention: gene expression analysis
Study NCT01414595 — intervention group
Intervention type: GENETIC
Intervention: polymorphism analysis
Study NCT01414595 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study NCT01414595 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Study NCT05980741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high-quality nursing
Description: High-quality nursing
Study NCT05980741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical Care Pathway
Description: Clinical Care Pathway
Study NCT05980741 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roy Adaptation Model
Description: Roy Adaptation Model
Study NCT04067336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: Oral administration
Study NCT01423136 — intervention group
Intervention type: DEVICE
Intervention: Remote ECG monitoring Spacelab SL 1050
Description: If ischemia noted, Sx will be notified and currently accepted treatments of myocardial ischemia will be recommended.
Study NCT02415569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Bowel Prep (2L PEG-ELP)
Description: Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
Study NCT05619952 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mushroom Powder
Description: Ground shiitake mushrooms or ground white button mushrooms
Study NCT03487172 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: poly-L-lactic acid to right knee
Description: Subjects will receive PLLA injections to the right knee and bacteriostatic water to the left.
Study NCT03487172 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: poly-L-lactic acid to left knee
Description: Subjects will receive PLLA injections to the left knee and bacteriostatic water to the right.
Study NCT02415569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L PEG-ELP and 10mg bisacodyl
Description: Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure.
Study NCT02415569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Bowel Prep (2L PEG-ELP)
Description: Subjects whose bristol stool forms are type 3 to 7, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
Study NCT02709252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVI and deltaPP after trendelenburg position change
Description: Comparison of hemodynamic parameters during surgery after position change
Study NCT02681744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: 24-weeks of progressive strength training
Study NCT00468650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sildenafil citrate
Description: Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.
Study NCT02468063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose terlipressin
Description: Terlipressin-2mg (low dose )
Study NCT01509846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine: 2.6±0.8 x 10^10 vp/mL, 3 doses
Description: Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^10 vp/mL administered on Days 0, 28, and 56
Study NCT01509846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine: 2.6±0.8 x 10^11 vp/mL, 3 doses
Description: Shigella flexneri 2a whole cell killed vaccine (Sf2aWC): 2.6±0.8 x 10\^11 vp/mL administered on Days 0, 28, and 56
Study NCT02468063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noradrenaline
Description: Noradrenaline at 7.5 mcg/min, maximum of 60mcg/min. stepped up every 15 min
Study NCT02468063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Noradrenaline
Description: Noradrenaline- 3.75 mcg/min to 30 mcg/min. stepped up every 15 min
Study NCT03201250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib:~Phase I: Level -1 = 20 mg or Level 0 = 40 mg or Level +1 = 60 mg, PO daily on days 1-28 Phase II: One of phase I dosing levels identified as MTD, PO daily on days 1-28~Carfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16~Dexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)
Study NCT02351583 — intervention group
Intervention type: DEVICE
Intervention: CytoCam
Description: The side-stream darkfield camera ( CytoCam) will be put under the subjects tongue for 5-10 minutes. Multiple pictures of the small blood vessels will be taken.
Study NCT02351583 — intervention group
Intervention type: DEVICE
Intervention: NIRS Artinis PortaLite with OxySoft softwear
Description: . The NIRS probe will be applied to one of the patient's thenar muscle and over the patient forehead and tissue oxygenation (TOI) will be recorded for 5 minutes.
Study NCT03365167 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LANAP (Laser Assisted New Attachment Procedure)
Description: radiation of Nd:YAG laser in periodontal pocket
Study NCT03365167 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: LANAP off
Description: radiation of Nd:YAG laser in off mode in periodontal pocket
Study NCT01509846 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: 1-3 doses
Description: Placebo administered on Day 0 (if 1 dose) or Day 0, 28, and 56 (3 doses)
Study NCT05508178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (100 µg)
Description: Norovirus: 50 µg GI.4 VLP + 50 µg GII.4 VLP without adjuvant
Study NCT01400919 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.
Description: Implantation of one or more study devices in the common and/or external iliac artery.
Study NCT01216696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first.
Study NCT01889212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 11C-erlotinib PET/CT
Study NCT01832935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: The starting dose of insulin Glargine was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
Study NCT01832935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin NPH
Description: The starting dose of insulin NPH was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
Study NCT04293094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 650
Description: AMG 650 administered orally as a tablet.
Study NCT01877226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol
Description: Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
Study NCT03957330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behaviour therapy
Description: All clients will receive the Wellbeing Course developed at Macquarie University, Australia. The Wellbeing Course is a transdiagnostic Internet-delivered cognitive behaviour intervention targeting symptoms of depressive and anxiety disorders. It comprises 5 online lessons targeting: 1) symptom identification and the cognitive behavioural model; 2) thought monitoring and challenging; 3) de-arousal strategies and pleasant activity scheduling; 4) graduated exposure; and 5) relapse prevention. Materials are presented in a didactic (i.e., text-based with visual images) and case-enhanced learning format (i.e., educational stories demonstrate the application of skills) and include homework activities. Lessons are released gradually in a standardized order over 8 weeks. Phone calls will only be made if there is a significant clinical issue requiring therapist attention that cannot be addressed over email (e.g., sudden increase in symptoms). Therapists will spend \~15 mins. per week/per client.
Study NCT05508178 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norovirus GI.4 / GII.4 Bivalent VLP Vaccine (300 µg)
Description: Norovirus: 150 µg GI.4 VLP + 150 µg GII.4 VLP without adjuvant
Study NCT05508178 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Norovirus vaccine (rNV-2v) vehicle without antigen
Study NCT02522169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: This is a randomized, prospective, parallel -controlled study, simple blinded and multicenter designed. Study centers are the Department of Child and Adolescent Medicine of the Ernst von Bergmann Hospital, Potsdam, and the Department of Child and Adolescent Medicine of Charité, Berlin.~We estimate a sample size of 50 patients per center. Study inclusion begins with given consent of the patient and the legal guardian. Patients will be randomized in control- and intervention group separately for Cohn's disease. An equal age and gender distribution is targeted for both control and intervention group. Sub groups will be formed depending on the time span from completed Infliximab induction to study enrollment (group A\< 6month, group B \< 6 month). Observation period is one year.
Study NCT02522169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: This is a randomized, prospective, parallel -controlled study, simple blinded and multicenter designed. Study centers are the Department of Child and Adolescent Medicine of the Ernst von Bergmann Hospital, Potsdam, and the Department of Child and Adolescent Medicine of Charité, Berlin.~We estimate a sample size of 50 patients per center. Study inclusion begins with given consent of the patient and the legal guardian. Patients will be randomized in control- and intervention group separately for Cohn's disease. An equal age and gender distribution is targeted for both control and intervention group. Sub groups will be formed depending on the time span from completed Infliximab induction to study enrollment (group A\< 6month, group B \< 6 month). Observation period is one year.
Study NCT02544750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study NCT03686878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lifitegrast
Description: Lifitegrast used twice a day
Study NCT03400410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Arm
Description: The educational video will be an overview with brief pros and cons of all types of available hormonal contraception. There will be emphasis on the importance of condom use as part of dual method protection.
Study NCT03301337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meat protein absorption
Description: Meat protein absorption when digested together with a full meal.
Study NCT04155528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: The intervention is listening to selected prerecorded music, specific Raga, on the individual CD player.
Study NCT04677543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALIS
Description: Inhalation via nebulization over approximately 6 to 15 minutes.
Study NCT04677543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Oral tablet
Study NCT04677543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azithromycin
Description: Oral tablet
Study NCT04677543 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Oral tablet
Study NCT04677543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ethambutol
Description: Oral tablet
Study NCT04677543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ELC
Description: Inhalation via nebulization over approximately 6 to 15 minutes.
Study NCT04192266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: 2.0 mg of estradiol will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions (Session 2- 6)
Study NCT04192266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: 2.0 mg placebo pills will be taken by mouth by the study participant 5-6 hours before each of 5 PE treatment sessions ( Sessions 2-6)
Study NCT02273037 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal heart rate Doppler
Description: A wind-up, handheld fetal heart rate monitor Doppler developed by Power-free Education Technology Doppler (www.pet.org.za)
Study NCT02273037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partograph
Description: Graphical documentation of labour progress, and maternal and fetal well-being.